# Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma

> **NCT00168727** · PHASE4 · COMPLETED · sponsor: **Biogen** · enrollment: 12 (—)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Lymphoma, Low-Grade

## Interventions

- **DRUG:** ibritumomab tiuxetan (Zevalin®)

## Key facts

- **NCT ID:** NCT00168727
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06-01
- **Primary completion:** —
- **Final completion:** 2005-10-31
- **Target enrollment:** 12 (—)
- **Last updated:** 2023-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00168727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00168727, "Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00168727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*